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Results: The median interval between HL and HF was 20.6 
years. Fifty-seven percent of the cases had died at the end of 
follow-up, with a median time from HF to death of 3.6 years 
(interquartile range: 0.2-5.6 years). Mediastinal radiotherapy 
was applied through parallel-opposed fields. Average MHD for 
cases treated with RT was 25 Gy and for controls 22 Gy. Risk 
of HF increased in a non-linear way, with no increase at a 
MHD of 10 Gy, a 1.2-fold increased risk at a MHD of 20 Gy, 
and a 2.5-fold increased risk at a MHD of 30 Gy. Relatively 
low doses of anthracyclines (10-279 mg/m2) were associated 
with a 3.2-fold increased risk of developing HF (95%CI: 1.3-
7.7) compared with patients who did not receive 
anthracyclines. High doses of anthracyclines (280-800 
mg/m2) were associated with a similarly increased risk (RR: 
2.8, 95%CI: 1.6-5.1). For patients who received 
anthracyclines in combination with mediastinal radiotherapy 
the risk of HF (RR: 2.90 at a MHD of 25 Gy) was slightly higher 
than the risk of mediastinal radiotherapy without 
anthracyclines (RR: 1.8 at a MHD of 25 Gy), although the 
difference was not statistically significant (p 
interaction=0.10). Classical risk factors for cardiovascular 
diseases did not confound or modify the association between 
treatment-related risk factors and HF risk. 
 
Conclusion: Risk of HF increased non-linearly with mean 
heart dose in patients treated for HL. Our findings can be 
used to predict HF risk and may therefore be useful for 
patients and doctors both before treatment, during radiation 
treatment planning and in follow-up. Patients who received 
both anthracyclines and mediastinal radiation need to be 
followed carefully. 
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Purpose or Objective: Among 6039 patients with Hodgkin 
lymphoma enrolled in nine successive EORTC-GELA 
randomized trials (1964-2004), the effect of individual 
radiotherapy and chemotherapy doses on the risk of 
developing cardiac disease was investigated. We specifically 
analysed the added value from radiation dose-volume metrics 
on cardiac risk prediction as well as the impact of relapse 
treatment. 
 
Material and Methods: For all patients, dose-volume metrics 
for the heart (mean dose, volume receiving ≥5 Gy (V5Gy), 
V10Gy, V20Gy, V30Gy, V40Gy) were retrospectively 
estimated by reconstructing individual treatments on 
representative computed tomography datasets. Cumulative 
doses of anthracyclines and vinca-alkaloids (mg/m2) were 
also obtained individually. Relapse occurring before a cardiac 
disease was analysed qualitatively (no, yes). Cardiac disease 
was reported during follow-up and through a patient-
reported questionnaire (LSQ responders, 2009-2010 cross-
sectional study). A multivariable Cox proportional hazards 
model with backwards selection was applied to test for 
patient- and treatment-related factors associated with 
cardiac disease. The resulting model was compared to a 
"mean heart dose"-model in terms of prognostic 
discrimination ability. 
 
Results: 599 patients developed at least one cardiac disease 
event (465 events obtained from the 1919 LSQ responders). 
Significant predictors of cardiac disease were: cumulative 
dose of anthracyclines (HR=1.002 per 1 mg/m2 increase in 
cumulative dose; 95% CI, 1.001-1.003, p=0.005); (any) 
treatment given for a relapse (HR=1.286; 95% CI,1.001-1.65, 
p=0.049) and the radiation dose-volume metrics V30Gy 
(HR=1.007 per 1% increase in dose; 95% CI, 1.003-1.011, 
p=0.001) and V40Gy (HR=1.018 per 1% increase in dose; 95% 
CI,1.008-1.029, p<0.001). The freedom from cardiac disease 
estimates with the "V30Gy, V40Gy"-model are plotted against 
a "mean heart dose"-model (= mean heart dose, cumulative 
dose of anthracyclines, any relapse treatment) in figure 1. 
 
 
Figure 1: Freedom from cardiac disease estimates with the 
resulting “V30Gy, V40Gy”-model versus a “mean heart dose”-
model. 
 
Conclusion: In patients treated for Hodgkin lymphoma, the 
radiation dose-volume metrics V30Gy and V40 Gy, the 
cumulative dose of anthracyclines, and (any) treatment given 
for a relapse have a significant impact on the risk of 
subsequent cardiac disease. There seems to be no improved 
discrimination ability of the prognostic model when using 
radiation dose-volume metrics compared to the mean heart 
dose metric. 
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Purpose or Objective: A novel approach to treatment 
planning for focal brachytherapy is described, utilizing a 
biologically-based inverse optimization algorithm and 
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biological imaging to target an ablative dose at known 
regions of significant tumour burden and a lower, therapeutic 
dose to low-risk regions. We describe our methods for 
defining target volume and prescription dose. 
 
Material and Methods: To demonstrate how tumour 
characteristics may be extracted from multi-parametric MRI 
(mpMRI) to inform the previously validated biological 
model(1), 21 patients underwent in vivo mpMRI prior to 
radical prostatectomy. Co-registration of histology and 
imaging data using rigid and deformable registration was 
validated by matching feature points and annotated zonal 
regions. Automated methods for defining tumour location, 
tumour cell density (TCD) and Gleason Score (GS) in histology 
were developed to provide high resolution ground truth 
data(2,3). Similarly, using ground truth histology data, 
machine learning methods have been developed and tested 
to predict tumour location in mpMRI. Further developments 
are underway to predict TCD, GS and hypoxia in mpMRI to 
build a multi-level voxel map defining tumour location and 
characteristics to inform the biological treatment planning 
model. 
 
Results: Co-registration of the in-vivo mpMRI with histology 
was achieved with an overall mean estimated error of 3.3 
mm (Fig 1).  
 
 
 
An ensemble-based supervised classification algorithm, 
trained on textural image features, demonstrates a highly 
sensitive method for automated tumour delineation in high 
resolution histology images(2). Colour deconvolution and the 
use of a radial symmetry transform provides measures of cell 
density, shown to highly correlate with an expert pathologist 
markup of tumour location(3). A Gaussian-kernel support 
vector machine demonstrated a tumour location predictive 
accuracy of >80% with potential for significant improvement 
using Bayesian methods to incorporate neighbourhood 
information. Similar statistical methods have demonstrated 
potential for mpMRI parameter/pharmacokinetic maps to be 
correlated with tumour characteristics including TCD, GS and 
hypoxia. Whilst imaging methods for hypoxia exist, providing 
reliable, high spatial resolution ground truth data remains 
challenging. 
 
Conclusion: A novel approach to focal brachytherapy 
planning has been developed that incorporates mpMRI 
parameter/pharmacokinetic maps to inform a biological 
model and an inverse optimisation algorithm to maximise 
tumour control probability and minimise dose to organs at 
risk in prostate brachytherapy. The model can be equally 
applied to low and high dose rate brachytherapy, and 
possibly EBRT with high precision treatment delivery 
techniques. 1) Haworth, A. et al. Brachytherapy. 12, 628-36, 
(2013). 2) DiFranco, D. et al., Proc. SPIE 9420 (2015). 3) 
Reynolds, H. et al.. Proc. SPIE 90410S (2014). 
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Purpose or Objective: A High-Dose-Rate Brachytherapy 
(HDR-BT) boost combined with external beam radiotherapy 
(EBRT) produced excellent long term outcome and is an 
alternative for escalated EBRT (>72 Gy) for low and 
intermediate risk prostate cancer (PC) patients. The question 
remains whether the use of HDR-BT results in lower 
complication rates for equal tumour control. The aim of this 
study was to compare HDR-BT/EBRT combined to EBRT-only 
in terms of long-term patient-reported toxicity and 
oncological outcome for low and intermediate risk PC 
patients. 
 
Material and Methods: Between 2000 and 2007 low and 
intermediate risk PC patients (n=231) were treated (stage 
T1b-T2a, G≤7, iPSA≤17) with a HDR -BT boost (3x6 Gy) 
combined with EBRT (25x1.8 Gy). Patients with a maximum 
prostate volume of 120 cc and a PSA, T-stage, and Gleason in 
the same range were selected (68 Gy: n=83, 78 Gy: n=74) 
from the Dutch randomized dose-escalation study (1997-
2003). At least 1 follow-up questionnaire had to be 
completed. Genitourinary (GU) and gastrointestinal (GI) 
toxicity symptoms were prospectively assessed using same 
questionnaires in the period 1-7y years post-treatment. 
Prevalence of long term GU and GI symptoms were calculated 
with intervals of 1 year and compared between treatment 
groups (chi-square test). Biochemical failure free survival 
(BFFS) using the Phoenix definition (stratified for Gleason 
score) was calculated and compared (log-rank test). 
 
Results: Median follow up was 8.8y for both 68 Gy and 78 Gy 
patients, and 6.8y for HDR-BT/EBRT. Median age was 69y and 
68y, respectively. In general, post-treatment GU complaints 
were comparable between groups (dysuria, nocturia, day 
frequency, incontinence). Rectal blood loss was significantly 
lower for HDR-BT compared to 78 Gy, from the first year of 
follow-up and onwards (p<0.001). Rectal discomfort 
(pain/cramps) was significantly lower at 3y follow-up 
(p<0.01). Rectal incontinence showed lower rates as well, 
but these were not significant (p=0.08). Differences in stool 
frequency ≥ 4 were small and not significant. BFFS rates at 7y 
were 79%, 90%, and 96% (68 Gy, 78 Gy, HDR-BT) for Gleason 
<7 and 43%, 75%, and 91% for Gleason 7. BFFS was 
significantly higher in both the HDR-BT and 78 Gy group 
compared to 68 Gy (p=<0.001 and p=0.034 respectively), the 
difference between HDR-BT and 78 Gy was not significant 
(p=0.11).  
 
Conclusion: HDR-BT/EBRT is associated with significantly 
lower long-term GI toxicity compared to escalated EBRT-only 
(78 Gy) with a favorably comparable 7 years tumor control. 
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Purpose or Objective: Implement routine in-vivo dosimetry 
in HDR prostate brachytherapy and develop error detection 
thresholds for real-time treatment monitoring. 
 
